The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes
    • eBooks

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Pathology Captures
Subscribe
Subscribe

False

The Pathologist / Issues / 2026 / November / AI Detects Hidden Pancreatic Cancer Signs
Endocrinology Biochemistry and molecular biology Clinical care Molecular Pathology

AI Detects Hidden Pancreatic Cancer Signs

An automated CT analysis tool identifies pancreatic cancer more than a year before clinical diagnosis, potentially opening new opportunities for early detection

11/18/2026 News 2 min read
  • Full Article
  • Summary
  • Takeaways
  • Listen
  • Scorecard
  • Quiz
  • Poll

Share

5 Key Takeaways
  • 1

    The Mayo Clinic-developed REDMOD analyzed subtle pancreatic tissue changes in CT scans that were not visible to experienced radiologists.

  • 2

    The study evaluated 1,462 CT scans, including 219 from patients who later developed pancreatic cancer and 1,243 from individuals without the disease.

  • 3

    In independent testing, REDMOD detected 73% of patients who later developed cancer, compared with 39% detected by radiologists; the median interval to diagnosis was 475 days.

  • 4

    REDMOD maintained 68% sensitivity in scans obtained more than 2 years before diagnosis, while external validation showed specificity ranging from 81% to 88%.

  • 5

    The retrospective study did not establish whether earlier detection improves survival, and prospective validation is needed; the model also incorrectly flagged about 1 in 5 cancer-free individuals.

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Newsletters

Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Your Privacy Choices
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.